Patrik Strömberg
Chief Executive Officer at AnaCardio AB
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Sara Mangsbo | M | - |
Strike Pharma AB
Strike Pharma AB Miscellaneous Commercial ServicesCommercial Services Strike Pharma AB is a Swedish company that specializes in developing therapeutic vaccines for solid tumors. The company is based in Uppsala, Sweden and was founded in 2020 by Pierre Dönnes and Sara Mangsbo. The company utilizes ADAC technology to create personalized immunotherapy for their patients. Mårten Winge has been the CEO of the company since 2021. | 4 years |
Lars Lund | M | - |
AnaCardio AB
AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | - |
Pierre Dönnes | M | - |
Strike Pharma AB
Strike Pharma AB Miscellaneous Commercial ServicesCommercial Services Strike Pharma AB is a Swedish company that specializes in developing therapeutic vaccines for solid tumors. The company is based in Uppsala, Sweden and was founded in 2020 by Pierre Dönnes and Sara Mangsbo. The company utilizes ADAC technology to create personalized immunotherapy for their patients. Mårten Winge has been the CEO of the company since 2021. | 4 years |
Gunilla Lundmark | F | 61 |
Strike Pharma AB
Strike Pharma AB Miscellaneous Commercial ServicesCommercial Services Strike Pharma AB is a Swedish company that specializes in developing therapeutic vaccines for solid tumors. The company is based in Uppsala, Sweden and was founded in 2020 by Pierre Dönnes and Sara Mangsbo. The company utilizes ADAC technology to create personalized immunotherapy for their patients. Mårten Winge has been the CEO of the company since 2021. | - |
Karin Hehenberger | M | 52 |
AnaCardio AB
AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | - |
Mårten Winge | M | 65 |
Strike Pharma AB
Strike Pharma AB Miscellaneous Commercial ServicesCommercial Services Strike Pharma AB is a Swedish company that specializes in developing therapeutic vaccines for solid tumors. The company is based in Uppsala, Sweden and was founded in 2020 by Pierre Dönnes and Sara Mangsbo. The company utilizes ADAC technology to create personalized immunotherapy for their patients. Mårten Winge has been the CEO of the company since 2021. | 3 years |
Christina Furebring | M | 60 |
Strike Pharma AB
Strike Pharma AB Miscellaneous Commercial ServicesCommercial Services Strike Pharma AB is a Swedish company that specializes in developing therapeutic vaccines for solid tumors. The company is based in Uppsala, Sweden and was founded in 2020 by Pierre Dönnes and Sara Mangsbo. The company utilizes ADAC technology to create personalized immunotherapy for their patients. Mårten Winge has been the CEO of the company since 2021. | 2 years |
Gunilla Anders Ekström | M | 66 |
Strike Pharma AB
Strike Pharma AB Miscellaneous Commercial ServicesCommercial Services Strike Pharma AB is a Swedish company that specializes in developing therapeutic vaccines for solid tumors. The company is based in Uppsala, Sweden and was founded in 2020 by Pierre Dönnes and Sara Mangsbo. The company utilizes ADAC technology to create personalized immunotherapy for their patients. Mårten Winge has been the CEO of the company since 2021. | 3 years |
Fredrik Lehmann | M | 48 |
AnaCardio AB
AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | - |
Maarten de Château | M | 61 |
Strike Pharma AB
Strike Pharma AB Miscellaneous Commercial ServicesCommercial Services Strike Pharma AB is a Swedish company that specializes in developing therapeutic vaccines for solid tumors. The company is based in Uppsala, Sweden and was founded in 2020 by Pierre Dönnes and Sara Mangsbo. The company utilizes ADAC technology to create personalized immunotherapy for their patients. Mårten Winge has been the CEO of the company since 2021. | - |
John Öhd | M | 53 |
AnaCardio AB
AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | - |
Johan Dighed | M | 51 |
AnaCardio AB
AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | - |
Magnus Persson | M | - |
Strike Pharma AB
Strike Pharma AB Miscellaneous Commercial ServicesCommercial Services Strike Pharma AB is a Swedish company that specializes in developing therapeutic vaccines for solid tumors. The company is based in Uppsala, Sweden and was founded in 2020 by Pierre Dönnes and Sara Mangsbo. The company utilizes ADAC technology to create personalized immunotherapy for their patients. Mårten Winge has been the CEO of the company since 2021. | - |
Charlotta Poehler | F | - |
AnaCardio AB
AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | - |
Karl Elmqvist | M | - |
AnaCardio AB
AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | 2 years |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
Sweden | 15 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Patrik Strömberg
- Personal Network